- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06296563
Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC
A Single Arm, Exploratory Clinical Study on the Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC
The goal of this clinical trial is to explore the efficacy and safety of combined infusion chemotherapy with Adebrelimab and Apatinib in the perioperative treatment of resectable intrahepatic cholangiocarcinoma patients. The main question it aims to answer are:
How to improve the survival of patients with intrahepatic cholangiocarcinoma and prolong the recurrence time after surgery.
Participants will receive receive neoadjuvant therapy with Adebrelimab combined with apatinib and FOLFOX-HAIC for 2 cycles (1 treatment cycle every 21 days, apatinib only used for the first cycle), and surgery was performed 14-28 days after the end of treatment. After 28 days of surgery, patients will continue to receive adjuvant treatment with Adebrelimab combined with apatinib for a maximum of one year.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Shandong
-
Jinan, Shandong, China, 250117
- Recruiting
- Shandong Cancer Hospital and Institute
-
Contact:
- Lei Zhao, MD
- Phone Number: +86 053167626368
- Email: drzhaolei@hotmail.com
-
Contact:
- Peifei Sun, MD
- Phone Number: +86 053167626242
-
Principal Investigator:
- Lei Zhao, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 1. Pathological diagnosis as malignant tumor of Intrahepatic Cholangiocarcinoma;
- 2. According to the UICC/AJCC TNM staging system (8th edition, 2017), resectable subjects were classified as Ib-IIIb stages;
- 3. aged ≥ 18 years at the time of signing the Informed consent form (ICF);
- 4. Expected survival time>3 months;
- 5. Both men and women are eligible;
- 6. The patient's Eastern Oncology Collaborative Group (ECOG) physical condition score is 0 or 1;
- 7. No serious complications, such as hypertension, coronary heart disease, or history of mental illness, and no history of severe allergies; Non pregnancy and non lactation period;
8. The organ and blood system functions of the subjects meet the following requirements:
- Absolute neutrophil count (ANC) ≥ 1.5 × 10 ^ 9/L;
- Platelet count ≥ 75 × 10 ^ 9/L;
- Hemoglobin ≥ 90 g/L;
- Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN);
- Aspartate aminotransferase (AST) and alanine aminotransferase ≤ 2.5 x ULN;
- Albumin ≥ 3g/dL
- Creatinine ≤ 1.5 x ULN
- 9. The subjects can understand and sign the informed consent form to participate in the experimental study; Good compliance.
- 10. Participants who have not undergone any local or systemic treatment for tumors in the past, and have undergone radical resection surgery for biliary tract cancer before recurrence for at least 2 years, can be included;
- 11. Subjects with potential fertility need to use a medically approved contraceptive measure (such as an intrauterine device, contraceptive pill, or condom) during the study treatment period and within one month after the end of the study treatment period; And within 72 hours before enrollment, the serum or urine HCG test must be negative and must be non lactating;
Exclusion Criteria:
- 1. Patients who received PD-1, PD-L1, PD-L2, or CTLA-4 inhibitors before enrollment, or patients who directly received another stimulating or co inhibitory T cell receptor (such as CTLA-4, CD137);
- 2. Use any other investigational drugs within 4 weeks prior to enrollment;
- 3. Any history of active autoimmune diseases or autoimmune diseases (such as interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism after hormone replacement therapy); Children with asthma who have completely improved in adulthood and do not require any intervention can be included, but patients who require intervention with bronchodilators cannot be included;
- 4. Congenital or acquired immunodeficiency, such as infection with human immunodeficiency virus (HIV), active hepatitis B (HBV DNA 500IU/ml), hepatitis C (hepatitis C antibody positive, HCV-RNA above the detection limit of the analysis method), or co infection with hepatitis B and hepatitis C;
- 5. Serious infection (such as intravenous infusion of antibiotics, antifungal or antiviral drugs) occurred within 4 weeks before the first administration, or unexplained fever>38.5 ° C occurred during screening/before the first administration;
- 6. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
- 7. Suffering from uncontrollable mental illness;
- 8. The simultaneous occurrence of serious and/or uncontrollable diseases may affect the participation of the study, such as unstable angina pectoris, myocardial infarction within 6 months, unstable symptomatic arrhythmia, symptomatic congestive heart failure, poorly controlled diabetes, serious activities, uncontrollable infection after insufficient biliary drainage (such as tumor blocking the bile duct);
- 9. Pregnancy (positive pregnancy test) or lactation period;
- 10. Other cancers that have occurred in the past (within the past 5 years) or simultaneously, excluding non melanoma skin cancer and in situ cancer;
- 11. History of allergy or hypersensitivity to any investigational drug;
- 12. Currently abusing alcohol or illegal drugs;
- 13. Unable or unwilling to sign informed consent form.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HAIC+Adebrelimab+apatinib
Neoadjuvant therapy with Adebrelimab combined with apatinib and FOLFOX-HAIC for 2 cycles (1 treatment cycle every 21 days, apatinib only used for the first cycle), and surgery was performed 14-28 days after the end of treatment.
After 28 days of surgery, patients will continue to receive adjuvant treatment with Adebrelimab combined with apatinib.
|
FOLFOX-hepatic artery infusion for 2 times.
Adebrelimab 1200mg, ivgtt, d1, q3w,up to one year of use at most.
Apatinib 250mg, po, qd,q3w,up to one year of use at most.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathologic complete response (pCR)
Time Frame: Up to one year
|
The proportion of subjects whose postoperative pathological examination did not detect residual cancer cells.
|
Up to one year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR)
Time Frame: Up to one year
|
Objective response rate
|
Up to one year
|
Overall Survival (OS)
Time Frame: Up to two years
|
Overall Survival:The survival time from enrollment to death from any cause.
|
Up to two years
|
Disease Control Rate (DCR)
Time Frame: Up to one year
|
Disease Control Rate: Ratio of complete response (CR)+partial response (PR)+stable disease (SD)
|
Up to one year
|
Event free survival (EFS)
Time Frame: Up to two years
|
The time from enrollment to the scheduled occurrence of events, including death, disease recurrence, disease progression, etc
|
Up to two years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHR1316-ICC-SD-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intrahepatic Cholangiocarcinoma
-
M.D. Anderson Cancer CenterActive, not recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic CholangiocarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Not yet recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic Cholangiocarcinoma | Oligometastatic Intrahepatic CholangiocarcinomaUnited States
-
Emory UniversityNational Cancer Institute (NCI)WithdrawnStage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Resectable Intrahepatic Cholangiocarcinoma | Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8 | Stage I Intrahepatic Cholangiocarcinoma AJCC v8United States
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH); CelgeneActive, not recruitingResectable Cholangiocarcinoma | Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8United States
-
Massachusetts General HospitalTerminatedResectable Intrahepatic Cholangiocarcinoma | Unresectable Intrahepatic CholangiocarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityActive, not recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Liver and Intrahepatic Bile Duct Carcinoma | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic CholangiocarcinomaUnited States
-
National Cancer Institute (NCI)CompletedStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Gallbladder Carcinoma | Metastatic Cholangiocarcinoma | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable CholangiocarcinomaUnited States
-
NRG OncologyNational Cancer Institute (NCI)TerminatedStage III Intrahepatic Cholangiocarcinoma | Stage IVA Intrahepatic CholangiocarcinomaUnited States, Canada
-
City of Hope Medical CenterNational Cancer Institute (NCI)WithdrawnBile Duct Adenocarcinoma | Stage III Intrahepatic Cholangiocarcinoma | Stage IVA Intrahepatic Cholangiocarcinoma | Stage IVB Intrahepatic CholangiocarcinomaUnited States
-
Rutgers, The State University of New JerseyRecruitingIntrahepatic Cholangiocarcinoma | Cholangiocarcinoma, IntrahepaticUnited States
Clinical Trials on HAIC
-
Second Affiliated Hospital of Guangzhou Medical...First Affiliated Hospital, Sun Yat-Sen University; First People's Hospital... and other collaboratorsRecruiting
-
Sun Yat-sen UniversityRecruitingHepatocellular Carcinoma | Potentially ResectionChina
-
Shandong Cancer Hospital and InstituteRecruitingIntrahepatic CholangiocarcinomaChina
-
Fudan UniversityRecruiting
-
Peking University Cancer Hospital & InstituteRecruitingAdvanced Hepatocellular Carcinoma (HCC)China
-
Zhongda HospitalRecruiting
-
Peking University Cancer Hospital & InstituteUnknownHepatocellular Carcinoma | Transarterial Chemoembolization
-
Tianjin Medical University Cancer Institute and...Not yet recruitingIntrahepatic CholangiocarcinomaChina
-
Fudan UniversityRecruitingIntrahepatic CholangiocarcinomaChina
-
Tianjin Medical University Cancer Institute and...Not yet recruitingIntrahepatic CholangiocarcinomaChina